CDMOs offering Solid-State Chemistry & Polymorph Screening with Oligonucleotide
8 published
8 published CDMOs match Solid-State Chemistry & Polymorph Screening and Oligonucleotide.
Locations in this set include United States, China, Switzerland, United Kingdom, Asia, and India.
Capabilities that show up most often in this set: Process Development, CMC Analytical Development, API Synthesis & Manufacturing, Small Molecule Development & Manufacturing, and Formulation Development.
Matching companies
Almac GroupGlobal CDMO with 7,900+ employees across 18 facilities, offering integrated drug development and manufacturing services including analytical development, formulation, process development, fill-finish, and specialized chemistry capabilities.
CatSciUK-based partner for small molecule and complex synthetic medicines, offering route selection, process development, GMP drug substance manufacture and analytical services across four European and UK sites.
CordenPharmaFull-service CDMO offering cGMP development and manufacturing of APIs, lipid excipients, drug products, injectables, peptides, LNPs, oligonucleotides, and oral solid dose across 10 facilities in 6 countries with 3000+ employees.
Crystec Limited (CrystecPharma)Crystec Limited (CrystecPharma) is a pharmaceutical technology company that offers its mSAS® supercritical-fluid particle engineering platform to improve the bioavailability, stability and delivery of small and large molecule therapeutics. Its work is aimed at clients developing new and existing medicines.
PharmaBlockLeading provider of innovative chemistry products and services for pharmaceutical R&D and commercial manufacturing, with expertise in process development, GMP manufacturing, and low-carbon chemistry solutions.
PortonPorton is a global CDMO offering integrated manufacturing and development services across small molecules, peptides, oligonucleotides, biologics, and conjugates with specialized capabilities in flow chemistry, biocatalysis, and advanced therapies.
Syngene InternationalInnovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
VeranovaGlobal CDMO specializing in development and manufacturing of complex active pharmaceutical ingredients (APIs), with expertise in solid form sciences, process development, and specialty modalities including ADCs and controlled substances.
Markdown mirror: /explore/solid-state-chemistry/oligonucleotide.md